In the article “Human Leucocyte Antigen Sensitisation and Its Impact on Transfusion Practice” [Transfus Med Hemother. 2019;46(5):356–369. https://doi.org/10.1159/000502158] by Weinstock et al., the authors found that the antigen Bgb was incorrectly associated with HLA-B18 instead of HLA-B17. HLA-B17 is part of the cross-reacting group 5C.
On page 362 in the paragraph “HLA Expression on Red Cells” the sentence “Bga correlated with the presence of HLA-B7 on the red cells, Bgb with HLA-B18, and Bgc with HLA-A28 (Table 1)” should read as follows: “Bga correlated with the presence of HLA-B7 on the red cells, Bgb with HLA-B17, and Bgc with HLA-A28 (Table 1).”
The corrected Table 1 is shown here.
© 2024 The Author(s) Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
